Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025. The release lists the total number of shares and total voting rights recorded on that date.

• ISIN: FR0010425595
• Date: 12/31/2025
• Total shares: 100,339,441
• Total voting rights: 105,576,356

Contact details for media and investor relations were provided for further information.

Key Figures

Total shares 100,339,441 Share capital as of 12/31/2025

Total voting rights 105,576,356 Voting rights as of 12/31/2025

Market Reality Check

$4.41 Last Close

Volume Volume 58,334 vs 20-day average 115,409 (relative volume 0.51). low

Technical Price 4.54 is trading above 200-day MA of 2.70.

Peers on Argus

Biotech peers like ENGN, FDMT, GLUE, KRRO and ABEO showed same-day declines (e.g., GLUE -5.08%), while CLLS was down -0.83%, suggesting modest, stock-specific movement rather than a coordinated sector momentum move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Arbitration outcome	Neutral	+2.4%	Arbitral Tribunal decision partially terminating a license and dismissing other claims.
Dec 08	Clinical data update	Positive	-2.5%	ASH 2025 Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.
Dec 03	Capital/voting report	Neutral	+3.6%	Monthly disclosure of total shares and voting rights as of November 30, 2025.
Nov 19	Scientific publication	Positive	+7.1%	Nature Communications paper on non-viral CssDNA gene insertion with high efficiency.
Nov 07	Earnings and update	Positive	+11.3%	Q3 2025 results with multiple CAR-T efficacy data points and stronger revenue.

Pattern Detected

Recent history shows strong positive reactions to major clinical and earnings updates, while an ASH 2025 clinical poster saw a negative move, indicating occasional divergence even on seemingly positive data.

Recent Company History

Over the last few months, Cellectis issued several clinically and strategically important updates. The Q3 2025 earnings and business update on Nov 7, 2025 and the non-viral gene editing paper on Nov 19, 2025 both saw notable positive price reactions. A routine monthly share-capital disclosure on Dec 3, 2025 also coincided with a gain. By contrast, an apparently positive ASH 2025 eti-cel update on Dec 8, 2025 was followed by a price decline, showing that market reception to clinical data has not been uniformly aligned.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-07-02

Cellectis has an effective Form F-3 shelf registration dated 2025-07-02, expiring 2028-07-02, with no recorded usage to date. This provides pre-cleared flexibility for future registered offerings, but no specific issuance or amount is indicated in the provided data.

Market Pulse Summary

The stock moved -5.4% in the session following this news. A negative reaction despite the routine nature of this monthly share-capital disclosure would resemble prior instances where price moves did not clearly track news importance, such as the decline after positive ASH 2025 data on Dec 8, 2025. Without a clear operational or financial surprise here, sustained weakness would more likely reflect broader positioning, sentiment, or reactions to earlier announcements rather than this filing alone.

Key Terms

isin financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

AI-generated analysis. Not financial advice.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Jan. 05, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
12/31/2025	100,339,441	105,576,356

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachment

• Voting_Rights_PR_December_2025_EN

FAQ

What are Cellectis (CLLS) total shares and voting rights as of December 31, 2025?

As of 12/31/2025, Cellectis reported 100,339,441 shares and 105,576,356 total voting rights.

Which market and ISIN does the Cellectis (CLLS) share capital notice reference?

The notice references Euronext Growth and ISIN FR0010425595.

Where can investors get more information about Cellectis (CLLS) share capital on January 5, 2026?

Investors can contact the provided investor relations email at investors@cellectis.com or the CFO contact listed in the release.

Does the December 31, 2025 report for Cellectis (CLLS) show a change in share count or voting rights?

The release provides the recorded totals for 12/31/2025; it does not include prior-period figures or an explicit change comparison.

Who are the media contacts listed for Cellectis (CLLS) regarding the December 2025 voting rights report?

Media contacts listed are Pascalyne Wilson and Patricia Sosa Navarro with phone numbers provided in the notice.